Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felicia S Falvella

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Pharmacogenetics and Genomics|January 7, 2017
HLA-B*57Felicia S Falvella, Stefania Cheli, Emilio Clementi
Frontiers in Pharmacology|June 18, 2015
LightSNiP assay is a good strategy for pharmacogenetics testStefania Cheli, Filippo Pietrantonio, Emilio Clementi, et al.
Journal of the National Cancer Institute|August 25, 2010
Promoter polymorphisms and transcript levels of nicotinic receptor CHRNA5Felicia S Falvella, Antonella Galvan, Francesca Colombo, et al.
Archives of Pathology & Laboratory Medicine|July 11, 2020
A Comprehensive Appraisal of Laboratory Biochemistry Tests as Major Predictors of COVID-19 SeverityElena Aloisio, Mariia Chibireva, Ludovica Serafini, et al.
Molecular Cancer|July 9, 2011
A 5'-region polymorphism modulates promoter activity of the tumor suppressor gene MFSD2AFrancesca Colombo, Felicia S Falvella, Antonella Galvan, et al.
Carcinogenesis|February 23, 2013
Multiple isoforms and differential allelic expression of CHRNA5 in lung tissue and lung adenocarcinomaFelicia S Falvella, Tiziana Alberio, Sara Noci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2009
Transcription deregulation at the 15q25 locus in association with lung adenocarcinoma riskFelicia S Falvella, Antonella Galvan, Elisa Frullanti, et al.
Journal of Clinical Pharmacy and Therapeutics|November 2, 2016
The combination of pharmacogenetic and pharmacokinetic analyses to optimize clomipramine dosing in major depression: a case reportStefania Antoniazzi, Alessandro Tatulli, Felicia S Falvella, et al.
Molecular Cancer|March 19, 2010
MFSD2A is a novel lung tumor suppressor gene modulating cell cycle and matrix attachmentMonica Spinola, Felicia S Falvella, Francesca Colombo, et al.
Therapeutic Drug Monitoring|January 4, 2017
Pharmacokinetics and Pharmacogenetics of Selective Serotonin Reuptake Inhibitors During Pregnancy: An Observational StudyLaura Pogliani, Felicia S Falvella, Dario Cattaneo, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Pharmacogenetics and Genomics|January 7, 2017
HLA-B*57Felicia S Falvella, Stefania Cheli, Emilio Clementi
Frontiers in Pharmacology|June 18, 2015
LightSNiP assay is a good strategy for pharmacogenetics testStefania Cheli, Filippo Pietrantonio, Emilio Clementi, et al.
Journal of the National Cancer Institute|August 25, 2010
Promoter polymorphisms and transcript levels of nicotinic receptor CHRNA5Felicia S Falvella, Antonella Galvan, Francesca Colombo, et al.
Archives of Pathology & Laboratory Medicine|July 11, 2020
A Comprehensive Appraisal of Laboratory Biochemistry Tests as Major Predictors of COVID-19 SeverityElena Aloisio, Mariia Chibireva, Ludovica Serafini, et al.
Molecular Cancer|July 9, 2011
A 5'-region polymorphism modulates promoter activity of the tumor suppressor gene MFSD2AFrancesca Colombo, Felicia S Falvella, Antonella Galvan, et al.
Carcinogenesis|February 23, 2013
Multiple isoforms and differential allelic expression of CHRNA5 in lung tissue and lung adenocarcinomaFelicia S Falvella, Tiziana Alberio, Sara Noci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2009
Transcription deregulation at the 15q25 locus in association with lung adenocarcinoma riskFelicia S Falvella, Antonella Galvan, Elisa Frullanti, et al.
Journal of Clinical Pharmacy and Therapeutics|November 2, 2016
The combination of pharmacogenetic and pharmacokinetic analyses to optimize clomipramine dosing in major depression: a case reportStefania Antoniazzi, Alessandro Tatulli, Felicia S Falvella, et al.
Molecular Cancer|March 19, 2010
MFSD2A is a novel lung tumor suppressor gene modulating cell cycle and matrix attachmentMonica Spinola, Felicia S Falvella, Francesca Colombo, et al.
Therapeutic Drug Monitoring|January 4, 2017
Pharmacokinetics and Pharmacogenetics of Selective Serotonin Reuptake Inhibitors During Pregnancy: An Observational StudyLaura Pogliani, Felicia S Falvella, Dario Cattaneo, et al.
Pageof 2